BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Moderna to supply 40 M COVID-19 vaccine doses to South Korea

December 31, 2020 | News

Potential distribution in South Korea expected to start in the second quarter of 2021



Moderna, Inc., a US based biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the company is engaged in discussions with the government of South Korea to potentially provide 40 million or more doses of the Moderna COVID-19 Vaccine to support South Korea's aim of providing vaccines to the public as soon as possible. Under the terms of the proposed agreement, distribution would begin in the second quarter of 2021.

The Moderna COVID-19 Vaccine has not been approved or licensed by U.S. Food and Drug Administration (FDA) or any other health authority, but FDA has authorized the vaccine for emergency use in individuals 18 years of age and older.

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases